2023 Fiscal Year Final Research Report
The analysis of non-leukemic cells in acute myeloid leukemia.
| Project/Area Number |
21K16261
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 54010:Hematology and medical oncology-related
|
|---|
| Research Institution | University of Tsukuba |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2021-04-01 – 2024-03-31
|
| Keywords | 急性骨髄性白血病 / 非腫瘍細胞 / 治療反応性 / 血液内科学 |
|---|
| Outline of Final Research Achievements |
In this study, we collected and stored peripheral blood mononuclear cell samples from patients with acute myeloid leukemia before, early after, and late after the start of treatment, and established a system to correlate these samples with various clinical information on patients with acute myeloid leukemia.
Next, gene expression analysis at the single cell level was performed. Contrary to expectations, there were no significant differences in changes in the cell counts of the leukemic cell population early after the start of treatment, regardless of the treatment effect. In addition, a portion of the lymphocyte population of non-leukemic cells increased early after treatment initiation, suggesting the possibility of treatment-related changes.
|
| Free Research Field |
血液内科学
|
| Academic Significance and Societal Importance of the Research Achievements |
急性骨髄性白血病は予後不良な疾患であり、治療効果の予測及び治療による有害事象の回避が重要である。本研究では通常用いられる骨髄を用いた場合に比較して、患者の侵襲を低減させ、頻回の検査を行うことが可能と考え、末梢血検体を用いて治療効果を予測することを目標とした。
治療前及び治療開始早期に遺伝子発現・細胞集団の変化について解析を行い、治療早期にリンパ球の一部において増加する集団を同定した。この変化が治療反応性を予想するかどうかに関して、さらなる解析を行い、患者に侵襲が少ない方法で早期に治療効果を予測する検査方法を確立する基礎となる知見となると考えている。
|
